Published • loading... • Updated
Health Funds a New Treatment Option for Patients with an Aggressive Lymphoma Subtype
Summary by laprovincia.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
elcorreogallego.esReposted by 
laprovincia.es
laprovincia.esAdult patients with Diffuse B Lymphoma of Large Cells (LBDCG) who have not yet received treatment and belong to one of the main molecular subtypes will have a new therapeutic option funded by the Ministry of Health. The authorisation is specifically aimed at patients with LBDCG IPI 2-5 of the ABC molecular subgroup, a variant that usually presents a more aggressive behavior and a less favorable response to conventional treatment.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
